Particle.news
Download on the App Store
6 ARTICLES
·
2h ago

India Clears Ozempic for Type 2 Diabetes, Paving Way for Near-Term Launch

The once-weekly GLP-1 injection is restricted to prescriptions for adults whose blood sugar remains uncontrolled with lifestyle measures.

With Ozempic Hitting India, We Answer All Your Top Questions About The Much Anticipated Weight Loss Drug - From Cost To Risks (Credits: iStock)
Drugs such as Ozempic make people crave food less and have now turned into a weight-loss drug.
Ozempic Set to Launch in India Soon

Overview

  • CDSCO approved Novo Nordisk’s semaglutide injection (Ozempic) on September 26 for adults with insufficiently controlled type 2 diabetes, with public reporting on September 30.
  • The Indian label specifies use as an adjunct to diet and exercise, and the product will be dispensed only on a doctor’s prescription, according to reporting.
  • Novo Nordisk is reported to be preparing a launch in India soon for the once-weekly shot, which mimics GLP-1 to improve insulin response and curb appetite.
  • Pricing for India has not been disclosed, and market watchers expect generic entries after a semaglutide patent expiry projected in March 2026 that could lower costs.
  • Coverage highlights trial-reported benefits such as HbA1c reduction, weight loss support, and cardiovascular and renal outcomes, alongside common gastrointestinal side effects including nausea.